Cancer (Including Haematology and Palliative Care)
1. Decision model for the cost of using opioids to treat cancer pain.
Presented at the EORTC First European Conference on the Economics of Cancer, Brussels, November 1997 and published in European Journal of Cancer 1997; 33(Suppl 9): S18.
2. Economic evaluation of the use of prophylactic clodronate to treat multiple myeloma.
Presented at the EORTC First European Conference on the Economics of Cancer, Brussels, November 1997 and published in European Journal of Cancer 1997; 33(Suppl 9): S25.
3. Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids.
Author: JF Guest, WM Hart & RF Cookson.
Source: PharmacoEconomics, 1998; 14(3): 285-297.
4. Economic impact of using clodronate in the management of patients with multiple myeloma.
Presented at the 38th Meeting of the British Society for Haematology, Glasgow, April 1998 and at the ISH-EHA Combined Haematology Congress, Amsterdam, July 1998.
5. Cost-effectiveness of amphotericin B plus G-CSF compared to amphotericin B in the treatment of a presumed deep-seated fungal infection in neutropenic patients in the UK.
Authors: TN Flynn, SM Kelsey, DL Hazel & JF Guest.
Source: Blood 1998; 92(10) Suppl 1 (part 2 of 2): Abstract no: 3746.
6. Cost-effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.
Authors: TN Flynn, SM Kelsey, DL Hazel & JF Guest.
Source: PharmacoEconomics 1999; 16(5,2): 543-550
7. The effect of treatment choices on the total cost of palliative care.
Author: R Twycross, M Fallon, K Sharma, C Hartley, JF Guest, WM Hart & E Wager.
Source: European Journal of Palliative Care, 1999; 6(3): 94-97
8. Economic impact of using clodronate in the management of patients with multiple myeloma.
Authors: NJ Bruce, EV McCloskey, JA Kanis & JF Guest.
Source: British Journal of Haematology. 1999; 104: 358-364.
9. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.
Authors: EV McCloskey, JF Guest & JA Kanis.
Source: Drugs 2001; 61 (9): 1253-1274
10. Treatment patterns and resource costs of palliative care for advanced cancer patients starting strong opioid treatment with 12-hourly sustained-release morphine or transdermal fentanyl.
Presented at the 10th World Congress on Pain, San Diego, August 2002.
11. A comparison of the resources used in advanced cancer care between two different strong opioids: An analysis of naturalistic practice in the UK.
Authors: JF. Guest, FJ Ruiz, J Russ, R Das Gupta, A Mihai & M Greener.
Source: Current Medical Research and Opinion. 2005; 21(2): 271-280
12. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.
Authors: JF Guest, A Davie, J Clegg and E McCloskey.
Source: Current Medical Research and Opinion. 2005; 21(5):805-15.
13. Cost implications of post-surgical morbidity following blood transfusion in cancer patients undergoing elective colorectal resection: an evaluation in the US hospital setting.
Authors: JF Guest, FJ Ruiz, R Tang, J-Y Wang, CR Changchien, S Wexner and MA Choti.
Source: Current Medical Research and Opinion. 2005; 21(3): 447-455.
14. Costs and consequences of using pamidronate compared with zoledronic acid in managing breast cancer patients in the UK.
Presented at the 10th Congress of the European Association of Hospital Pharmacists, Lisbon, March 2005
15. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK.
Authors: JF Guest, FJ Ruiz, MJ Greener and IF Trotman.
Source: European Journal of Cancer Care. 2006; 15:65-73.
<<< Go Back